首页> 美国卫生研究院文献>Aging (Albany NY) >Prognostic value of subclinical thyroid dysfunction in ischemic stroke patients treated with intravenous thrombolysis
【2h】

Prognostic value of subclinical thyroid dysfunction in ischemic stroke patients treated with intravenous thrombolysis

机译:亚临床甲状腺功能不全在缺血性卒中静脉溶栓治疗中的预后价值

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Data regarding the association between subclinical thyroid dysfunction and clinical outcomes in ischemic stroke patients with intravenous thrombolysis (IVT) are limited. We aimed to investigate the predictive value of subclinical thyroid dysfunction in END, functional outcome and mortality at 3 months among IVT patients. We prospectively recruited 563 IVT patients from 5 stroke centers in China. Thyroid function status was classified as subclinical hypothyroidism, subclinical hyperthyroidism (SHyper) and euthyroidism. The primary outcome was END, defined as ≥ 4 point in the NIHSS score within 24 h after IVT. Secondary outcomes included 3-month functional outcome and mortality. Of the 563 participants, END occurred in 14.7%, poor outcome in 50.8%, and mortality in 9.4%. SHyper was an independent predictor of END [odd ratio (OR), 4.35; 95% confidence interval [CI], 1.86–9.68, P = 0.003], 3-month poor outcome (OR, 3.24; 95% CI, 1.43–7.33, P = 0.005) and mortality [hazard ratio, 2.78; 95% CI, 1.55–5.36, P = 0.003]. Subgroup analysis showed that there was no significant relationship between SHyper and clinical outcomes in IVT patients with endovascular therapy. In summary, SHyper is associated with increased risk of END, and poor outcome and mortality at 3 months in IVT patients without endovascular therapy.
机译:关于缺血性卒中静脉溶栓(IVT)患者亚临床甲状腺功能不全与临床结局之间相关性的数据有限。我们旨在调查IVT患者在3个月内亚临床甲状腺功能不全对END,功能结局和死亡率的预测价值。我们前瞻性地从中国5个卒中中心招募了563名IVT患者。甲状腺功能状态分为亚临床甲状腺功能减退,亚临床甲状腺功能亢进(SHyper)和甲状腺功能正常。主要结局是END,定义为IVT后24小时内NIHSS评分≥4分。次要结局包括3个月的功能结局和死亡率。在563名参与者中,END发生率为14.7%,不良结局率为50.8%,死亡率为9.4%。 SHyper是END [奇数比(OR),4.35; 95%置信区间[CI]为1.86-9.68,P = 0.003],3个月不良结局(OR为3.24; 95%CI为1.43-7.33,P = 0.005)和死亡率[危险比为2.78; 95%CI,1.55-5.36,P = 0.003]。亚组分析显示,接受血管内治疗的IVT患者SHyper与临床结局之间无显着相关性。总之,在没有血管内治疗的IVT患者中,SHyper与END风险增加以及3个月的不良预后和死亡率相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号